Table 7.
Sensitivity analyses of randomised controlled trials of calcium supplements and risk of fracture
| Analysis and fracture site | No of studies | Relative risk (95% CI) |
|---|---|---|
| Include Inkovaara 198313 and Larsen 200414* | ||
| Total fracture | 22 | 0.90 (0.83 to 0.96) |
| Include Inkovaara 198313 and Larsen 200414† | ||
| Total fracture | 22 | 0.89 (0.83 to 0.95) |
| Analyse Chapuy 199415 16 as individually randomised | ||
| Total fracture | 20 | 0.88 (0.81 to 0.96) |
| Hip fracture | 13 | 0.95 (0.76 to 1.18) |
| Restrict Jackson 20069 to women not using oestrogen19 | ||
| Hip fracture-all studies | 13 | 1.04 (0.80 to 1.34) |
| Hip fracture-CaD subgroup | 9 | 0.90 (0.75 to 1.08) |
| Hip fracture-community dwelling | 11 | 1.20 (0.97 to 1.48) |
| Hip fracture-calcium intake >800 mg/d | 6 | 1.41 (0.92 to 2.18) |
| Exclude Chapuy 199415 16 | ||
| Total fracture | 19 | 0.90 (0.82 to 0.98) |
| Hip fracture | 12 | 1.02 (0.78 to 1.34) |
*Comparison of both environmental programme and calcium and vitamin D programme with environmental programme only.
†Comparison of any calcium and vitamin D versus no calcium and vitamin D.